Unmet Clinical Need

Luminal diseases can lead to blockages in blood vessels or tubular structures in your body. Metallic and synthetic-covered stents are used to open these structures; however, your body may recognize the implants as foreign materials and respond with a negative reaction. This rejection leads to numerous complications including restenosis, inflammation, infection, allergic responses, scarring and thrombosis.

Amnion-covered stents may alleviate the complications associated
with metallic and synthetic-covered stents.

Technology

AMStent™ Solution

The AMStent™ is the first stent fully covered in amnion tissue, a proven biomaterial with regenerative properties. It has the promise to keep lumens open longer with potentially fewer complications than bare metal stents, covered stents or drug-eluting stents.

AMStent Device Photo

A Proven Biomaterial that Promotes Healing

More than 100 years of clinical history with a growing list of applications

  • Wound and burn management
  • Ocular tissue reconstruction
  • Spine surgery adhesion barrier
  • Reconstructive and plastic surgery

Favorable biologic properties and safety profile

  • Supports natural endothelialization and the regeneration of healthy tissue
  • Anti-inflammatory property minimizes the foreign body response
  • Anti-microbial property reduces the risk of infection
  • Anti-fibrotic property minimizes obstructive granuloma formation
  • Anti-thrombotic property minimizes thrombus formation

 

A Platform Technology that Solves Challenges in Luminal Disease Treatment

Designed to restore and maintain long-term lumen patency

  • The AMStent™ combines the regenerative properties of amnion tissue and mechanical properties of a stent frame

Thin, compliant amnion allows for stent delivery through a smaller catheter

  • A 10 mm AMStent™ can be delivered using an 8 Fr catheter, unlike other covered stents of that size which require an 11 Fr catheter

A Tracheobronchial Stent Designed for
Palliative Care to Improve Quality of Life

The AMStent™ is fully covered in amnion tissue, which provides a bed for natural endothelialization to support the regeneration of healthy tissue

  • Healthy re-epithelialization re-establishes mucociliary escalation and minimizes migration

Complication/reintervention rates for current metallic tracheal stents range approximately 20-40%1-10

  • Anti-microbial and anti-inflammatory properties of the amnion tissue may minimize complications and mitigate reintervention

 

References
  1. Breitenbücher A, et al. Long-term follow-up and survival after Ultraflex stent insertion in the management of complex malignant airway stenoses. Respiration. 2008;75(4):443-9. doi: 10.1159/000119053. Epub 2008 Mar 20.
  2. Chhajed PN, et al. Therapeutic bronchoscopy for malignant airway stenoses: choice of modality and survival. J Cancer Res Ther. 2010 Apr-Jun;6(2):204-9. doi: 10.4103/0973-1482.65250.
  3. Han X, et al. Individualized airway-covered stent implantation therapy for thoracogastric airway fistula after esophagectomy. Surg Endosc. 2017 Apr;31(4):1713-8. doi: 10.1007/s00464-016-5162-9. Epub 2016 Aug 12.
  4. Lemaire A, et al. Outcomes of tracheobronchial stents in patients with malignant airway disease. Ann Thorac Surg. 2005 Aug;80(2):434-7; discussion 437-8.
  5. Marchese R, et al. Fully covered self-expandable metal stent in tracheobronchial disorders: clinical experience. Respiration. 2015;89(1):49-56. doi: 10.1159/000368614. Epub 2015 Jan 15.
  6. McGrath EE, et al. The insertion of self expanding metal stents with flexible bronchoscopy under sedation for malignant tracheobronchial stenosis: a single-center retrospective analysis. Arch Bronconeumol. 2012 Feb;48(2):43-8. doi: 10.1016/j.arbres.2011.09.008. Epub 2011 Dec 2.
  7. Miyazawa T, et al. Implantation of ultraflex nitinol stents in malignant tracheobronchial stenosis. CHEST. 2000;69(2):398-401.
  8. Nasir BS, et al. Palliation of Concomitant Tracheobronchial and Esophageal Disease Using a Combined Airway and Esophageal Approach. Ann Thorac Surg. 2016 Aug;102(2):400-6. doi: 10.1016/j.athoracsur.2016.03.021. Epub 2016 May 5.
  9. Razi SS, et al. Timely airway stenting improves survival in patients with malignant central airway obstruction. Ann Thorac Surg. 2010 Oct;90(4):1088-93. doi: 10.1016/j.athoracsur.2010.06.093.
  10. Saad CP, et al. Self-expandable metallic airway stents and flexible bronchoscopy: long-term outcomes analysis. Chest. 2003 Nov;124(5):1993-9.

Our Company

Peytant Solutions is a biomedical device company developing Regenerative Stent Technology™. Our vision is to transform the treatment of luminal diseases through regenerative medicine.

Purpose

To improve the quality of life for patients worldwide by utilizing regenerative biomaterials to provide transformational solutions for luminal diseases.

Guiding Values

Respect for the human tissue

We recognize the source of our unique biomaterial and will always treat it with the utmost respect.

Innovate and improve

We strive to develop new products that improve patient quality of life, advance physicians' ability to treat luminal disease and lower healthcare system costs.

Customers first

We are committed to being responsive to our customers and earning their trust every day.

Do the right thing

We will hold ourselves to the highest standards of quality and integrity in everything we do.

Success through results

We are accountable for delivering on our commitments and recognize that success requires a winning attitude, discipline, and a sense of urgency.

Dedicated and virtual team

We will foster an environment for our talented team members to excel and contribute at the highest level.

Leadership Team

Bringing experience from both large medical technology companies and high-growth entrepreneurial companies.

John has 35 years of experience in executive management, sales and marketing, as well as product and business development for medical device and pharmaceutical companies. He has expertise in the interventional and surgical sectors of the pulmonary, gastroenterology, trans-vascular heart, and pharmaceutical markets. Formerly, John served as General Manager for the Global Pharmaceutical Injectable Division of Baxter International, President and General Manager of SuperDimension, Inc. (acquired by Covidien) and President and CEO of HeartStent. Prior to those positions, John was Vice President and Business Unit Manager for the Schneider (USA) Division of Pfizer and Vice President for Boston Scientific.
Steve has extensive medical device experience with over 35 years in the industry. He has held senior positions in the cardiovascular segment, including President, Cardiac Surgery at St. Jude Medical, CEO at Lumen Biomedical and Director of Sales and Marketing at the Schneider (USA) Division of Pfizer. In the orthopedic segment, Steve was previously President at Zimmer Spine, General Manager of Global Spine at Zimmer Biomet Spine and CEO at Disc Dynamics. He currently serves as Chairman of the Board at BioVentrix, Inc.
Clay is the former President and CEO of Reglera (acquired by Dohmen Life Science Services), a regulatory and quality assurance consulting firm. He has more than 25 years' experience in quality, regulatory, operations and management in the medical device and human tissue bank industries. Clay's personal expertise includes new technology development and regulatory submissions/approval as well as combination and unique tissue products. He previously worked for COBE Laboratories/GAMBRO Healthcare and Alcon Laboratories.
Dr. Chambers is an interventional cardiologist with Metropolitan Heart and Vascular Institute, President of Metropolitan Cardiovascular Consultants - Minneapolis, and the Director of the Lipid Clinic. His professional interests include coronary artery disease and cardiovascular research. He is a graduate of Wayne State University and University of Minnesota Medical School.
Bruce has spent more than 40 years in the practice of business law, with a primary emphasis on small to medium-sized companies, including medical device and pharmaceutical companies. His expertise includes commercial transactions such as licensing and supply arrangements, debt and equity financing, and regulatory matters. Bruce received degrees from Yale Law School and University of Iowa.
Craig M. Walker, M.D., is the Founder, President and Medical Director of Cardiovascular Institute of the South in Houma, Louisiana. Additionally, Dr. Walker is a Clinical Professor of Medicine at Tulane University School of Medicine and LSU School of Medicine in New Orleans. He is board certified in internal medicine, cardiovascular disease and interventional cardiology.
Dr. Walker founded and is the chairman for one of the largest cardiovascular conferences in the nation, New Cardiovascular Horizons (NCVH), to educate and train medical professionals on the latest techniques to treat coronary and peripheral vascular disease. He also maintains the distinction title of primary investigator for several cardiovascular and peripheral devices. Through his extensive knowledge and research in peripheral vascular disease, Dr. Walker provides educational training courses to physicians from around the world.

Contact

Peytant Solutions, Inc.
3650 Annapolis Lane North, #180
      Plymouth, MN 55447
(763) 316-6937

Send Us a Message